ASTERDM · NSE
Aster DM Quality Care Limited
₹755.05
-0.74% (-₹5.6)
Prev. close
₹760.65
Volume
16,16,337
Delivery %
61.9%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Aster DM Quality Care Limited
Aster DM Quality Care Limited operates as an integrated healthcare provider in India. The company operates through four healthcare brands including Aster DM, CARE Hospitals, Evercare, and KIMSHEALTH. It offers comprehensive healthcare services including primary, secondary, tertiary and quaternary care across key areas including oncology, cardiac sciences, neurosciences, gastro sciences, orthopedics, nephrology, organ transplantation, mother and childcare, and critical care. In addition, the company operates retail pharmacies and optical outlets. Aster DM Quality Care Limited was formerly known as Aster DM Healthcare Limited and changed its name to Aster DM Quality Care Limited in July 2026. The company was founded in 1987 and is based in Hyderabad, India.
Details
Sector
Healthcare
Industry
Medical Care Facilities
CEO
Mr. S. Ramesh Kumar
Headquarters
Bengaluru
Website
asterqualitycare.comExchange
View on NSE ↗Key stats
Market cap
₹65,815.63 Cr
P/E ratio (TTM)
122.6
Dividend yield
0.53%
EPS (TTM)
₹6.16
Beta (1Y · daily vs NIFTY 50)
0.40
Beta (5Y · monthly vs NIFTY 50)
0.80
Shares float
34.62 Cr
EPS · quarter ended Jun 2026
₹0.31
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹8,608.43 Cr | ₹10,253.28 Cr | ₹2,951.80 Cr | ₹3,698.90 Cr | ₹4,138.46 Cr | ₹4,643.22 Cr | |
| EBITDA | ₹1,112.76 Cr | ₹1,533.91 Cr | ₹1,061.05 Cr | ₹1,355.03 Cr | ₹833.31 Cr | ₹954.54 Cr |
| ₹147.74 Cr | ₹525.99 Cr | ₹424.91 Cr | ₹129.28 Cr | ₹5,377.83 Cr | ₹388.14 Cr | |
| Diluted EPS | ₹2.97 | ₹10.57 | ₹8.54 | ₹2.6 | ₹107.85 | ₹7.52 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹11,620.00 Cr | ₹12,521.00 Cr | ₹14,836.00 Cr | ₹17,983.00 Cr | ₹6,600.00 Cr | ₹8,112.00 Cr | |
| — | ₹4,907.13 Cr | ₹5,700.30 Cr | ₹1,383.75 Cr | ₹2,017.77 Cr | ₹2,219.66 Cr | |
| Stockholders' equity | ₹3,372.46 Cr | ₹3,953.41 Cr | ₹4,448.07 Cr | ₹4,559.79 Cr | ₹3,428.07 Cr | ₹4,575.86 Cr |
Total debt, Long-term debt, Current (short-term) debt, Others have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,569.00 Cr | ₹1,314.00 Cr | ₹1,834.00 Cr | ₹158.00 Cr | ₹425.00 Cr | ₹656.00 Cr | |
| Investing cash flow | ₹-330.30 Cr | ₹-570.48 Cr | ₹-971.88 Cr | ₹-884.65 Cr | ₹6,014.87 Cr | ₹-288.21 Cr |
| ₹-1,116.00 Cr | ₹-686.00 Cr | ₹-817.00 Cr | ₹1,053.00 Cr | ₹-6,358.00 Cr | ₹-304.00 Cr | |
| Capital expenditure | ₹-386.44 Cr | ₹-547.97 Cr | ₹-848.23 Cr | ₹-805.58 Cr | ₹-356.73 Cr | ₹-477.52 Cr |
| End cash position | ₹234.55 Cr | ₹299.33 Cr | ₹365.07 Cr | ₹697.46 Cr | ₹164.59 Cr | ₹228.07 Cr |
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21 | Mar 22 | Jun 22–Sep 22(2Q) | Dec 22 | Mar 23 | Jun 23 | Sep 23 | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Apr 25 | Jun 25 | Sep 25–Mar 26(3Q) | Jun 26 | Jul 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 37.88% | 37.88% | 37.88% | 37.88% | 37.88% | 41.88% | 41.88% | 41.88% | 41.88% | 41.88% | 41.88% | 41.88% | 41.88% | 41.89% | 40.38% | 40.39% | 40.39% | 40.39% | 53.72% |
| Public | 61.64% | 61.65% | 61.66% | 61.67% | 61.67% | 57.69% | 57.70% | 57.70% | 57.75% | 57.77% | 57.80% | 57.82% | 57.84% | 57.85% | 59.37% | 59.36% | 59.38% | 59.61% | 46.28% |
| Employee trusts | 0.48% | 0.47% | 0.46% | 0.45% | 0.44% | 0.43% | 0.42% | 0.41% | 0.37% | 0.35% | 0.32% | 0.30% | 0.28% | 0.26% | 0.25% | 0.25% | 0.23% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Aster DM Quality Care Limited | ₹66,303.77 Cr | ₹755.05 | 123.7 | 14.49 | 8.5% | 0.49 | +12.2% | +23.0% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Concall transcripts
Show all 11
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
17 indices
Weight is a free-float market-cap-share estimate from NSE’s live index data, not NSE’s own published (and sometimes capped) index weight. Indices without a live weight feed are listed without one, in alphabetical order after the weighted ones.